Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus

Trial Profile

Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Insulin peglispro (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Feb 2015 Planned End Date changed from 1 Mar 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov
    • 09 Feb 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top